Here is a capture from Faron’s slide. The analysis planned for 2028, based on which response rates will be reviewed, the dose for Phase 3 will be selected, the situation will be updated with the FDA, etc. The dataset is naturally crucial for partnering and the realization of Phase 3 as a whole.
9 Likes